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found an additional UTI caused by E. 
coli 12 weeks later. Thus, because of 
the long duration of carriage of this 
highly resistant strain, potential for 
transmission to others is high.
The low number of previous re-
ports of community-acquired ESBL in 
the United States does not necessarily 
suggest low community prevalence. 
Reports of ESBL-producer bacteremia 
in patients visiting emergency rooms 
suggests earlier and wider incidence 
(8). Returning to the practice of regu-
larly culturing urine samples is diffi -
cult to justify; however, without ongo-
ing surveillance to detect and control 
ESBL resistance, prevalence can only 
be expected to rise. 
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Leishmania killicki 
Imported from 
Tunisian Desert
To the Editor: In North Africa, 
cutaneous leishmaniasis (CL) is a 
widespread zoonosis transmitted by 
sandfl ies. In Tunisia, 3 Leishmania 
species are responsible for CL: L. ma-
jor, L. infantum, and L. killicki.  L. ma-
jor causes 2,000–4,000 zoonotic CL 
infections each year. L. infantum, the 
usual agent of visceral leishmaniasis, 
may be implicated in sporadic CL in 
northern Tunisia (dermotropic strains 
coexist with viscerotropic strains of 
L. infantum in these areas). L. killicki 
was fi rst described in the desert region 
of Tataouine, Tunisia, in 1986 (1) and 
is the agent of chronic CL. We report 
a case of chronic CL caused by L. kil-
licki, imported to Europe by a woman 
who had traveled to Tunisia.
 A 76-year-old woman, with no 
relevant medical history, sought treat-
ment from a dermatologist in Greno-
ble, France, for a cutaneous lesion on 
her right arm. This lesion had appeared 
2 months after she returned from a July 
2007 trip to Tunisia, where she spent 2 
weeks in the desert riding camels and 
sleeping under a tent. The cutaneous 
lesion was isolated, round, 10 mm in 
diameter, ulcerative, surrounded by 
infl ammation, and painless; no lymph-
adenopathy was found. The patient 
had no lesions on her mucous mem-
branes and no concomitant general 
signs or symptoms. Given the absence 
of substantial signs or symptoms, the 
patient had paid no particular attention 
to this lesion until it became second-
arily infected with bacteria. The sec-
ondary infection resolved after treat-
ment with antimicrobial drugs, but the 
lesion persisted and a diagnosis of CL, 
presumably caused by L. major, was 
suggested.
Histologic investigation of a skin 
scraping showed amastigotes of Leish-
mania spp., but no further identifi ca-
tion was done at that time. No treat-
ment was given because the lesion was 
isolated and on the arm and because 
L. major lesions frequently heal spon-
taneously. After 2 months, the lesion 
had not healed, and Leishmania amas-
tigotes were still found in scrapings. 
After 8 months, the lesion became in-
fl amed, and a skin scraping sample was 
sent to the National Reference Center 
of Leishmania in Montpellier, France. 
DNA was extracted, and L. killicki 
was identifi ed by genotyping. Various 
therapeutic options were considered, 
but no clear treatment recommenda-
tions were found. Parenteral therapy 
(pentavalent antimonials, pentamidine 
isethionate, or amphotericin B) was 
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not used because of adverse effects of 
these drugs. Miltefosine, used for vis-
ceral leishmaniasis (2), was an option 
because it can be taken orally and is 
well tolerated: however, its effective-
ness for CL has mostly been evalu-
ated for South American forms of CL, 
and its effectiveness for other forms is 
still not clear (3). Given the patient’s 
older age and the fact that lesion was 
isolated, intralesional treatment with 
meglumine antimoniate was initiated. 
After 9 weekly injections, the lesion 
disappeared (10 months after onset).
CL caused by L. killicki is called 
chronic CL because lesions persist for 
years, as opposed to CL caused by L. 
major, for which lesions usually re-
solve without treatment after a few 
months. L. killicki was fi rst considered 
to appear sporadically in limited areas, 
but a recent study found new foci in 
southern Tunisia (partly overlapping 
an L. major–endemic area) (4,5) and in 
neighboring countries such as Algeria 
(6) and Libya (7). Depending on the 
identifi cation method used (multilocus 
enzyme electrophoresis or multilocus 
microsatellite typing), L. killicki is 
considered to be either a separate spe-
cies or a variety of L. tropica (8,9). 
Although fewer L. killicki cases have 
been reported (<20 cases since 1986), 
L. killicki infections differ from L. 
tropica infections because transmis-
sion seems strictly zoonotic (versus 
mostly anthroponotic for L. tropica) 
and because the clinical signs seem to 
be restricted to a chronic cutaneous le-
sion resistant to standard treatment.
The case reported here highlights 
the effect of ecotourism on imported 
diseases; journeys that were previ-
ously considered adventurous (i.e., 
physically challenging) are now easily 
accessible to anyone, thanks to the op-
eration of well-organized tours. When 
treating travelers, clinicians must be 
aware of the specifi c epidemiology of 
disease agents in the regions visited. 
This case also shows the diffi culties en-
countered when selecting treatment for 
leishmaniasis because it is still consid-
ered a neglected tropical disease, and 
thus the development of effective and 
nontoxic drug treatments has not been 
a priority. Lastly, this case shows how 
travelers can potentially spread rare 
diseases. Reservoirs and vectors can 
also be imported to other regions as a 
result of urbanization, climate change, 
and exportations. These factors lead to 
changes in environmental conditions 
favorable to spread of anthroponotic 
Leishmania spp. (urbanization) or 
to the establishment of tropical and/
or subtropical vector species (global 
warming), and Leishmania strains can 
be exported through dogs. Specifi c 
species of Leishmania are no longer 
circumscribed to particular regions. In 
Europe, controlling this vector-borne 
disease seems essential because leish-
maiasis is already endemic to southern 
Europe and new species may be intro-
duced (10).
CL caused by L. killicki will 
probably soon become more common 
among persons who travel throughout 
North Africa. Because of the chronic 
evolution of CL lesions, clinicians 
should characterize the Leishmania 
strain and, if necessary, adapt their pa-
tient care to the strain.
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